Normophthal / Lys-Glu: ocular angiogenesis use — RU2177801C1
В.Х. Хавинсон, В.М. Хокканен, С.В. Трофимова, В.В. Малинин · 2002 · RU2177801C1 · patent family 20245157
Published 2002-01-10.
Reported patent results
Reported findings
The patent describes faster improvement in corneal inflammation and reduced neovascular activity with adjunctive Lys-Glu.
Lys-Glu adjunctive ocular reports: corneal disease 39 patients/71 eyes versus 16/30; posterior-eye disease 34/67 versus 12/24.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Corneal comparison | Faster reduction of photophobia, tearing and inflammation than conventional care reported | 39 treated versus 16 comparison patients; numerical between-group estimate not extracted |
| Posterior-eye report | Scotoma number/size reportedly decreased in 87.3% of cases; perifocal edema disappeared in 52.4% and decreased in 43.2% | The percentages’ patient-versus-eye denominators are not sufficiently explicit |
| Illustrative posterior-eye case | Visual acuity 0.4 → 0.6 | Single patient receiving concurrent treatment · By the end of the course |
Nonrandomized mixed-disease reports and ambiguity between patient and eye denominators limit interpretation. Group visual-acuity tables were not transcribed; these are patent reports, not proof of anti-VEGF-equivalent benefit.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The claim explicitly identifies L-Lys-L-Glu in an ophthalmic angiogenesis-inhibition use. This is the same defined sequence discussed for Vilon, with a different proposed application.
A shared sequence does not make every branded formulation equivalent, and an ocular method claim does not establish human visual benefit.
- Publication
- RU2177801C1 ↗ · 2002-01-10
- Earliest priority / filing
- 2001-01-25 / 2001-01-25
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20245157 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent inhibiting angiogenesis in visual organ disease
Inventors: В.Х. Хавинсон; В.М. Хокканен; С.В. Трофимова; В.В. Малинин.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A shared sequence does not make every branded formulation equivalent, and an ocular method claim does not establish human visual benefit.
- Nonrandomized mixed-disease reports and ambiguity between patient and eye denominators limit interpretation. Group visual-acuity tables were not transcribed; these are patent reports, not proof of anti-VEGF-equivalent benefit.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20245157. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: В.Х. Хавинсон, В.М. Хокканен, С.В. Трофимова, В.В. Малинин. Normophthal / Lys-Glu: ocular angiogenesis use — RU2177801C1 RU2177801C1 · patent family 20245157 2002.
Molekul research summary: https://molekul.io/research/patent-ru2177801c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Normophthal
Named ocular peptide preparation with a 45-patient 2013 journal comparison and a separately labeled institute-report trail. Favorable narrative findings coexist with nonsignificant table labels; chemical identity and current-product equivalence require confirmation.
Vilon
Defined Lys–Glu (KE) dipeptide with historical adjunct-treatment reports in type 1 diabetes and separate laboratory research. Immune and coagulation-marker findings do not establish autoimmune disease modification.